drugset / Trial / NCT04212169

Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis

NCT04212169

Phase 2 Completed 148 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.

Timeline

Start
2019-12-09
Primary completion
2022-07-21
Completion
2022-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Tozorakimab Monoclonal antibody

Indications